Psychiatric pharmacogenomics in pediatric psychopharmacology

Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):773-88. doi: 10.1016/j.chc.2012.07.001.

Abstract

This article provides an overview of where psychiatric pharmacogenomic testing stands as an emerging clinical tool in modern psychotropic prescribing practice, specifically in the pediatric population. This practical discussion is organized around the state of psychiatric pharmacogenomics research when choosing psychopharmacologic interventions in the most commonly encountered mental illnesses in youth. As with the rest of the topics on psychopharmacology for children and adolescents in this publication, a clinical vignette is presented, this one highlighting a clinical case of a 16 year old genotyped during hospitalization for recalcitrant depression.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Child
  • Cytochrome P-450 Enzyme System / drug effects
  • Cytochrome P-450 Enzyme System / genetics*
  • Cytochrome P-450 Enzyme System / metabolism
  • Female
  • Humans
  • Male
  • Mental Disorders / drug therapy*
  • Mental Disorders / genetics
  • Mental Disorders / metabolism
  • Pharmacogenetics*
  • Psychopharmacology*
  • Psychotropic Drugs / metabolism
  • Psychotropic Drugs / pharmacology*
  • Psychotropic Drugs / therapeutic use
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / genetics*
  • Receptors, Dopamine / metabolism
  • Receptors, Serotonin / drug effects
  • Receptors, Serotonin / genetics*
  • Receptors, Serotonin / metabolism

Substances

  • Psychotropic Drugs
  • Receptors, Dopamine
  • Receptors, Serotonin
  • Cytochrome P-450 Enzyme System